U.S. - Vaccines For Human Medicine - Market Analysis, Forecast, Size, Trends and Insights
Get instant access to more than 2 million reports, dashboards, and datasets on the IndexBox Platform.
View PricingVaccines Prices in the United States
U.S. Vaccines Export Price in December 2021
In December 2021, the vaccines price stood at $2.1K per kg (FOB, US), declining by -13.7% against the previous month. Overall, the export price, however, showed a measured increase. The most prominent rate of growth was recorded in June 2021 an increase of 130% against the previous month. Over the period under review, the average export prices hit record highs at $3.9K per kg in September 2021; afterwards, it flattened through to December 2021.
Prices varied noticeably by the country of destination: the country with the highest price was the Philippines ($3.9K per kg), while the average price for exports to France ($206 per kg) was amongst the lowest.
From January 2021 to December 2021, the most notable rate of growth in terms of prices was recorded for supplies to Mexico (+62.2%), while the prices for the other major destinations experienced more modest paces of growth.
U.S. Vaccines Exports
In December 2021, vaccines exports from the United States surged to 1.2K tons, jumping by 50% against November 2021. Overall, exports posted significant growth. The growth pace was the most rapid in March 2021 when exports increased by 204% month-to-month. The exports peaked in December 2021.
In value terms, vaccines exports soared to $2.4B (IndexBox estimates) in December 2021. Over the period under review, exports recorded a significant expansion. The most prominent rate of growth was recorded in May 2021 with an increase of 352% month-to-month. Over the period under review, the exports attained the maximum at 2.9M tons in September 2021; however, from October 2021 to December 2021, the exports stood at a somewhat lower figure.
U.S. Vaccines Exports by Country
Brazil (184 tons), Belgium (108 tons) and Pakistan (106 tons) were the main destinations of vaccines exports from the United States, with a combined 34% share of total exports. Indonesia, Bangladesh, the Philippines, Mexico, Vietnam, Nigeria, the Netherlands, Peru, France and Chile lagged somewhat behind, together comprising a further 40%.
From January 2021 to December 2021, the most notable rate of growth in terms of shipments, amongst the main countries of destination, was attained by Bangladesh (with a CAGR of +183.6%), while the other leaders experienced more modest paces of growth.
In value terms, Pakistan ($265M), the Philippines ($263M) and Indonesia ($215M) appeared to be the largest markets for vaccines exported from the United States worldwide, together accounting for 31% of total exports. These countries were followed by Brazil, Bangladesh, Belgium, Vietnam, Mexico, Nigeria, Peru, Chile, the Netherlands and France, which together accounted for a further 31%.
Bangladesh, with a CAGR of +223.9%, saw the highest rates of growth with regard to the value of exports, among the main countries of destination over the period under review, while shipments for the other leaders experienced more modest paces of growth.
This report provides an in-depth analysis of the vaccine market in the U.S.. Within it, you will discover the latest data on market trends and opportunities by country, consumption, production and price developments, as well as the global trade (imports and exports). The forecast exhibits the market prospects through 2030.
Product coverage:
- Prodcom 21202140 -
- Prodcom 21202145 - Vaccines for human medicine
Country coverage:
- United States
Data coverage:
- Market volume and value
- Per Capita consumption
- Forecast of the market dynamics in the medium term
- Trade (exports and imports) in the U.S.
- Export and import prices
- Market trends, drivers and restraints
- Key market players and their profiles
Reasons to buy this report:
- Take advantage of the latest data
- Find deeper insights into current market developments
- Discover vital success factors affecting the market
This report is designed for manufacturers, distributors, importers, and wholesalers, as well as for investors, consultants and advisors.
In this report, you can find information that helps you to make informed decisions on the following issues:
- How to diversify your business and benefit from new market opportunities
- How to load your idle production capacity
- How to boost your sales on overseas markets
- How to increase your profit margins
- How to make your supply chain more sustainable
- How to reduce your production and supply chain costs
- How to outsource production to other countries
- How to prepare your business for global expansion
While doing this research, we combine the accumulated expertise of our analysts and the capabilities of artificial intelligence. The AI-based platform, developed by our data scientists, constitutes the key working tool for business analysts, empowering them to discover deep insights and ideas from the marketing data.
-
1. INTRODUCTION
Making Data-Driven Decisions to Grow Your Business
- REPORT DESCRIPTION
- RESEARCH METHODOLOGY AND AI PLATFORM
- DATA-DRIVEN DECISIONS FOR YOUR BUSINESS
- GLOSSARY AND SPECIFIC TERMS
-
2. EXECUTIVE SUMMARY
A Quick Overview of Market Performance
- KEY FINDINGS
- MARKET TRENDS This Chapter is Available Only for the Professional Edition PRO
-
3. MARKET OVERVIEW
Understanding the Current State of The Market and Its Prospects
- MARKET SIZE
- MARKET STRUCTURE
- TRADE BALANCE
- PER CAPITA CONSUMPTION
- MARKET FORECAST TO 2030
-
4. MOST PROMISING PRODUCT
Finding New Products to Diversify Your Business
This Chapter is Available Only for the Professional Edition PRO- TOP PRODUCTS TO DIVERSIFY YOUR BUSINESS
- BEST-SELLING PRODUCTS
- MOST CONSUMED PRODUCT
- MOST TRADED PRODUCT
- MOST PROFITABLE PRODUCT FOR EXPORT
-
5. MOST PROMISING SUPPLYING COUNTRIES
Choosing the Best Countries to Establish Your Sustainable Supply Chain
This Chapter is Available Only for the Professional Edition PRO- TOP COUNTRIES TO SOURCE YOUR PRODUCT
- TOP PRODUCING COUNTRIES
- TOP EXPORTING COUNTRIES
- LOW-COST EXPORTING COUNTRIES
-
6. MOST PROMISING OVERSEAS MARKETS
Choosing the Best Countries to Boost Your Exports
This Chapter is Available Only for the Professional Edition PRO- TOP OVERSEAS MARKETS FOR EXPORTING YOUR PRODUCT
- TOP CONSUMING MARKETS
- UNSATURATED MARKETS
- TOP IMPORTING MARKETS
- MOST PROFITABLE MARKETS
7. PRODUCTION
The Latest Trends and Insights into The Industry
- PRODUCTION VOLUME AND VALUE
8. IMPORTS
The Largest Import Supplying Countries
- IMPORTS FROM 2012–2024
- IMPORTS BY COUNTRY
- IMPORT PRICES BY COUNTRY
9. EXPORTS
The Largest Destinations for Exports
- EXPORTS FROM 2012–2024
- EXPORTS BY COUNTRY
- EXPORT PRICES BY COUNTRY
-
10. PROFILES OF MAJOR PRODUCERS
The Largest Producers on The Market and Their Profiles
This Chapter is Available Only for the Professional Edition PRO -
LIST OF TABLES
- Key Findings In 2024
- Market Volume, In Physical Terms, 2012–2024
- Market Value, 2012–2024
- Per Capita Consumption In 2012-2024
- Imports, In Physical Terms, By Country, 2012–2024
- Imports, In Value Terms, By Country, 2012–2024
- Import Prices, By Country Of Origin, 2012–2024
- Exports, In Physical Terms, By Country, 2012–2024
- Exports, In Value Terms, By Country, 2012–2024
- Export Prices, By Country Of Destination, 2012–2024
-
LIST OF FIGURES
- Market Volume, In Physical Terms, 2012–2024
- Market Value, 2012–2024
- Market Structure – Domestic Supply vs. Imports, In Physical Terms, 2012-2024
- Market Structure – Domestic Supply vs. Imports, In Value Terms, 2012-2024
- Trade Balance, In Physical Terms, 2012-2024
- Trade Balance, In Value Terms, 2012-2024
- Per Capita Consumption, 2012-2024
- Market Volume Forecast to 2030
- Market Value Forecast to 2030
- Products: Market Size And Growth, By Type
- Products: Average Per Capita Consumption, By Type
- Products: Exports And Growth, By Type
- Products: Export Prices And Growth, By Type
- Production Volume And Growth
- Exports And Growth
- Export Prices And Growth
- Market Size And Growth
- Per Capita Consumption
- Imports And Growth
- Import Prices
- Production, In Physical Terms, 2012–2024
- Production, In Value Terms, 2012–2024
- Imports, In Physical Terms, 2012–2024
- Imports, In Value Terms, 2012–2024
- Imports, In Physical Terms, By Country, 2024
- Imports, In Physical Terms, By Country, 2012–2024
- Imports, In Value Terms, By Country, 2012–2024
- Import Prices, By Country Of Origin, 2012–2024
- Exports, In Physical Terms, 2012–2024
- Exports, In Value Terms, 2012–2024
- Exports, In Physical Terms, By Country, 2024
- Exports, In Physical Terms, By Country, 2012–2024
- Exports, In Value Terms, By Country, 2012–2024
- Export Prices, By Country Of Destination, 2012–2024
467
This report provides an in-depth analysis of the vaccine market in the U.S..
439
This report provides an in-depth analysis of the antisera market in the U.S..
537
This report provides an in-depth analysis of the biological product market in the U.S..
332
This report provides an in-depth analysis of the veterinary medicine vaccines market in the U.S..
391
This report provides an in-depth analysis of the market for human and animal blood in the U.S..
2595
This report provides an in-depth analysis of the global vaccine market.
1984
This report provides an in-depth analysis of the global antisera market.
428
This report provides an in-depth analysis of the global biological product market.
646
This report provides an in-depth analysis of the global veterinary medicine vaccines market.
497
This report provides an in-depth analysis of the global market for human and animal blood.
118
U.S. experts predict a smaller winter COVID wave, posing challenges for Pfizer amid declining revenues, emphasizing the need to diversify non-COVID products.
245
Explore Moderna's ongoing phase three norovirus vaccine trial targeting urgent prevention needs amid rising outbreaks in the U.S.
212
Moderna has secured $590 million to enhance pandemic influenza vaccine development, focusing on mRNA technology and expanding human trials.
96
Moderna's shares increased by over 10% due to progress in H5N1 vaccine development following a human fatality in the U.S.
119
Haleon invests $54M in its U.S. R&D centre to drive innovation in consumer healthcare, enhancing its product pipeline and maintaining competitive edge.
599
For the seventh year in a row, the U.S. biological product market recorded growth in sales value, which increased by...
70
In the period of 2018 to 2024, the growth of exports for Human And Animal Blood failed to regain momentum. The value of exports declined to $3.5B in 2024.
1361
From February 2023 to December 2023, the exports of Human And Animal Blood saw a significant decline, dropping to $71M in value.
108
Moderna cuts 2025 sales forecast by $1 billion due to weak RSV and COVID-19 vaccine demand, prompting strategic shifts and cost reductions.
168
Explore the top import markets for vaccines and discover key statistics on their import values. Learn about the growing global demand for vaccines and the role of key countries in meeting vaccination needs.
